Summary:
This is a double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
Qualified Participants Must:
Be diagnosed with Alzheimer's and be 65 to 90 years old
Qualified Participants May Receive:
Compensation for time and travel, may receive investigational medication or placebo.